Brain TumorGLIOLINCT05571579
Biological Collection of Brain Tumors
An observational study of Brain Tumor, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
The objective of this study is to build a collection of biological samples from patients with brain tumors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Brain Tumor
- What is being tested?
- blood and/or csf collection
- How many people
- 500 participants
- Where
- 1 siteFrance
- Study dates
- 22 Nov 2023to 22 Nov 2033
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patient with brain tumor
Who may be able to join
- Patient whose diagnosis of brain tumor has been confirmed.
- Adult patients, from 18 years old and without upper age limit
- Patient affiliated to a social security scheme or equivalent.
- Patient able to consent, having dated and signed an informed consent
Who cannot join
- Pregnant or breastfeeding women
- Patient under guardianship or curators.
- Persons deprived of their liberty by a judicial or administrative decision
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Hospices Civils de Lyon
Bron, Rhône, 69500
François Ducray, Pr, 04 72 68 13 21 ext. +33, francois.ducray@chu-lyon.fr
Appoline Barthelmé, 04 26 73 97 87 ext. +33, Apolline.barthelme@chu-lyon.fr
About this study
Official title: Biological Collection of Brain Tumors - GLIOLI Collection
The objective of this study is to build a collection of biological samples from patients with brain tumors.
- Conditions
- Brain Tumor
- Being tested
- blood and/or csf collection
- Keywords
- Brain tumor
- Medical subject headings
- Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood and/or csf collectionBiological
blood and/or collection
Only once :
- 1 tube of blood of 4 mL on dry tube with or without gel,
- 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection.
| Study group | Role | What they receive |
|---|---|---|
| brain tumors | Not described Receives: Biological: blood and/or csf collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
number of biological samples
number of biological samples
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Oct 2022
- Study start22 Nov 2023
- Primary completion22 Nov 2033 (estimated)
- Study completion22 Nov 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain TumorStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05571579
- Sponsor's protocol ID
- 69HCL22_0813
- Acronym
- GLIOLI
- Status last verified
- Jan 2026
- First submitted
- 3 Oct 2022
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biological Collection of Brain Tumors - GLIOLI Collection
- ClinicalTrials.gov ID
- NCT05571579
- Acronym / sponsor ID
- GLIOLI / 69HCL22_0813
- Conditions
- Brain Tumor
- Keywords
- Brain tumor
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 22 Nov 2023 (actual)
- Primary completion
- 22 Nov 2033 (estimated)
- Study completion
- 22 Nov 2033 (estimated)
- First posted
- 7 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to build a collection of biological samples from patients with brain tumors.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| brain tumors | – | Biological: blood and/or csf collection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patient with brain tumor
Key inclusion criteria (4 listed)
- Patient whose diagnosis of brain tumor has been confirmed.
- Adult patients, from 18 years old and without upper age limit
- Patient affiliated to a social security scheme or equivalent.
- Patient able to consent, having dated and signed an informed consent
Key exclusion criteria (3 listed)
- Pregnant or breastfeeding women
- Patient under guardianship or curators.
- Persons deprived of their liberty by a judicial or administrative decision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood and/or csf collectionblood and/or collection Only once : * 1 tube of blood of 4 mL on dry tube with or without gel, * 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection. | Biological | brain tumors |
Primary outcome
number of biological samples
Time frame: 10 years
number of biological samples
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Individual participant dataSharing planned: No
Related trials for Brain Tumor
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain Tumor, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact François DUCRAY, Pr (04 72 68 13 21 ext. +33, francois.ducray@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
number of biological samples (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.